Navigation Links
Generic Onslaught Makes Drug Pricing Decisions More Critical Than Ever
Date:1/3/2008

NEW YORK, Jan. 3 /PRNewswire/ -- In an era of expanding competition from generics, expiring patent protection for many top-selling drugs, and a slowdown in new drug discoveries, there is very little margin for error in drug pricing decisions. A new report by Kalorama Information entitled Drug Pricing and Reimbursement Strategies: Preparing for the Coming Generic Onslaught gives pharmaceutical companies the information they need to reevaluate their pricing strategies to remain profitable in a changing marketplace.

Pharmaceutical sales reached $643.0 billion worldwide in 2006, increasing by 6.5% over the previous year, and global pharmaceutical companies have enjoyed a median profitability more than three times the average for all Fortune 500 companies. But companies will be challenged in the coming years: in addition to the onslaught of generics, which have increased their market penetration from 44% to 51.6% in the last couple of years, shrinking government and corporate healthcare budgets are putting pressure on the pricing strategies of pharmaceutical and biotech companies and reducing their margins. After eight years of double-digit growth, commercial prescription drug costs decreased to the single digits in 2003 and settled at a 4.8% growth rate in 2005.

"The golden years of monopolistic pricing in the United States are gone," notes the report's author, Joseph Constance. "Medicare Part D initiation, tiered managed care formulary systems, and the increasing clout of generic medicines are challenging margins now. Companies will have to adapt to survive, and pricing is one of the few levers they can pull."

Kalorama Information's report, Drug Pricing and Reimbursement Strategies: Preparing for the Coming Generic Onslaught provides considerable detail on this all-important area of pharmaceutical marketing strategy in the United States, Europe and Japan. It not only exposes the current business environment for pharmaceuticals, but also details strategies for specific results, including: gaining and defending market share through the cautious application of penetration pricing, enhancing brand loyalty with the 'bait and hook' tactic, as well as strategies for gaining new customers, improving margins and utilizing capacity. The report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Guide-Drug-Pricing-1422997, and is also available at http://www.MarketResearch.com.

About Kalorama Information

Kalorama Information supplies the latest in independent market research on medical markets. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit http://www.KaloramaInformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
2. Generic Prescription Drugs Show Increasingly Greater Use in Southeastern Pennsylvania
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
4. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
5. New OIG Report Confirms Part D Plans Are Driving Generic Utilization
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Watson Files FDA Application for Generic YAZ(R)
8. Giant Eagle Expands Popular Generic Prescription Program and Now Offers 400 for $4
9. Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg
10. Barrs Generic Version of Estrostep(R) Fe Tablets Approved
11. Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of ... its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his ... July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming ...
(Date:10/13/2017)... Ill. (PRWEB) , ... October ... ... Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer ... healthcare professionals on guideline updates for the primary prevention of cardiovascular diseases ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
Breaking Medicine Technology: